Management of hemorrhage in gastrointestinal stromal tumors: a review

Qi Liu1
Fanmin Kong1
Jianping Zhou1
Ming Dong1
Qi Dong2

1Department of Gastrointestinal Surgery, The First Hospital, China Medical University, Shenyang, China;
2Department of General Surgery, The People’s Hospital, China Medical University, Shenyang, China

Abstract: Gastrointestinal stromal tumors (GISTs) are relatively common mesenchymal tumors. They originate from the wall of hollow viscera and may be found in any part of the digestive tract. The prognosis of patients with stromal tumors depends on various risk factors, including size, location, presence of mitotic figures, and tumor rupture. Emergency surgery is often required for stromal tumors with hemorrhage. The current literature suggests that stromal tumor hemorrhage indicates poor prognosis. Although the optimal treatment options for hemorrhagic GISTs are based on surgical experience, there remains controversy with regard to optimum postoperative management as well as the classification of malignant potential. This article reviews the biological characteristics, diagnostic features, prognostic factors, treatment, and postoperative management of GISTs with hemorrhage.

Keywords: GIST, hemorrhage of digestive tract, prognosis, targeted therapy

Introduction

Gastrointestinal stromal tumors (GISTs) are common mesenchymal tumors. They originate from the luminal wall and may occur in any part of the digestive tract. Most GISTs occur in the stomach (60%–70%) or the small intestine (25%–35%). The colon, rectum, appendix (5%), and esophagus (2%–3%) are relatively rare sites.1,2 They may even occur outside the digestive tract, including in the greater omentum, mesentry, and retroperitoneal sites.3 The size of most stromal tumors is about 5 cm at diagnosis.4 Approximately 70% of GIST patients are symptomatic. There are a wide variety of clinical manifestations, including rare presentations as part of the syndrome, known as Carney’s triad: gastric stromal tumor, pulmonary chondroma, and paraganglioma. They are also seen in neurofibromatosis type 1.5,6 Stromal tumors of the small intestine often present as abdominal pain and hemorrhage of the digestive tract. Rectal stromal tumors may manifest as hematochezia and obstruction.7 Gastrointestinal bleeding is a relatively common presentation.8,9 Prognosis varies by location.

Because of the interference of various factors and limitations of the research samples, the classification of malignant potential of GISTs and postoperative management remains controversial. Age and gender may be the prognostic factors: it has been reported that the prognosis of women aged <50 years is better than that of women aged >50 years10 and that GISTs are more common in women aged 50–70 years.11 This last study also suggests that obesity may be a protective factor for patients with stromal tumors.12 The 2016.v2 National Comprehensive Cancer Network (NCCN) guidelines suggest that patients with high-risk factors for recurrence (tumor...
size >5 cm with large numbers of mitotic figures (>5/50 high-power field), tumor rupture, or recurrence risk >50%) should be treated with oral Gleevec postoperatively for at least 36 months to reduce the risk of recurrence. However, there is controversy, as reported in Table 1, over the risk degrees for assessing malignant potential of GISTs.

Some investigators believe that gastrointestinal bleeding is caused by tumor invasion of the mucosa layer, resulting in ulceration, while tumor rupture occurs mostly in the serosa. Recently, many studies have reported that prognosis of GISTs with gastrointestinal bleeding is relatively poor compared with patients without bleeding. Recently, researchers have found that gastrointestinal bleeding may be an independent risk factor for recurrence. According to the 2012 edition of the Guidelines for the European Society of Oncology, GISTs of different malignant potential levels require different postoperative treatment and management. Although the emergence of targeted drugs such as imatinib has improved prognosis of stromal tumors more than that of other malignant tumors, there is also an incidence of adverse outcomes that lead to tumor recurrence and metastasis due to irregular treatment.

### Molecular classifications and clinicopathological features of GIST

The average age of patients diagnosed with stromal tumors is 60 years. There are no significant epidemiological differences with respect to gender, ethnicity, or location. The prevailing hypothesis is that GISTs originate from the interstitial cells of Cajal in the muscularis propria and the myenteric plexus. Cell morphologies are characterized as spindle cell (70%), epithelioid cell (20%), and mixed cell (10%).

Table 1: The different risk degrees for assessing malignant potential of GISTs

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;2 cm and ≤5 mitotic index</td>
<td>Unknown</td>
<td>-</td>
</tr>
<tr>
<td>≤5 cm and ≤5 mitotic index</td>
<td>Very low</td>
<td>&lt;2 cm and ≤5 mitotic index</td>
</tr>
<tr>
<td>Gastric: &gt;5 cm and ≤5 mitotic index</td>
<td>Low</td>
<td>2–5 cm and ≤5 mitotic index</td>
</tr>
<tr>
<td>Others: 2–5 cm and ≤5 mitotic index</td>
<td>Intermediate</td>
<td>5–10 cm and ≤5 mitotic index</td>
</tr>
<tr>
<td>Gastric: &gt;10 cm and ≤5 mitotic index or &gt;2–5 cm and &gt;5 mitotic index</td>
<td>High</td>
<td>&gt;5 cm and 6–10 mitotic index</td>
</tr>
<tr>
<td>Others: 5–10 cm and ≤5 mitotic index</td>
<td></td>
<td>&gt;5 cm and &gt;5 mitotic index</td>
</tr>
<tr>
<td>Gastric: &gt;5 cm and &gt;5 mitotic index</td>
<td></td>
<td>10 cm and any mitotic index</td>
</tr>
<tr>
<td>Others: &gt;10 cm and &gt;5 mitotic index</td>
<td></td>
<td>Any size and &gt;10 mitotic index</td>
</tr>
</tbody>
</table>

**Abbreviation:** AFIP, Armed Forces Institute of Pathology; GISTs, gastrointestinal stromal tumors; NIH, National Institutes of Health.

The expression of these markers plays an important role in regulating cell proliferation, differentiation, adhesion, and apoptosis. CD117 is currently recognized as one of the most significant markers of immune expression in stromal tumors. Hirota and other investigators have found that most GISTs produce genetic mutations, mostly in c-KIT. Approximately 90% of GISTs are associated with mutations in c-KIT, affecting the expression of exons 9, 11, 13, and 17. These mutations lead to continuous activation of tyrosine kinases, leading to cell proliferation and inhibition of apoptosis. These are the targets of tyrosinase inhibitors, such as imatinib. The distribution proportion of these mutations is approximately as follows: exon 11 (57%–71%); exon 9 (10%–18%); exon 13 (1%–4%); and exon 17 (1%–4%). The most frequent mutation in exon 11 is gene deletion, usually between codons 550 and 579, especially the codon 557–559. However, in c-KIT-negative GISTs, another tyrosine kinase receptor, called platelet-derived growth factor receptor alpha (PDGFRA), has also been identified. Most PDGFRA mutations affect exon 18 and less commonly exons 12 and 14. Overall, the PDGFRA gene mutation is estimated to account for 5%–10% of GISTs. It has been documented that 80% of PDGFRA mutations occur in the stomach and omental tissue.

Approximately 10% of adult GISTs are not associated with KIT or PDGFRA mutations, while some stromal tumors do not harbor any known gene mutations. These are called “wild-type” tumors. These may arise from other pathogeneses, such as deficiency of succinate dehydrogenase or BRAF mutations.

The pathological features of GISTs are closely related to prognosis. The Z90001 study by the American College of Surgeons Oncology Group found that the tumor size, location, and mitotic figure number are the most important factors affecting recurrence-free survival, as opposed to type of gene mutation. The classification of gene mutation often
determines postoperative management and treatment, so it is important to improve gene analysis.

Common clinical manifestations and diagnostic features of GISTs

Clinical features
The clinical manifestations of GISTs are atypical and non-specific, depending on tumor size, location, and other factors. The most common clinical presentations are gastrointestinal bleeding and abdominal discomfort. Gastrointestinal bleeding accounts for about 30%–40%, abdominal pain 20%–50%, obstruction 10%–30%, and asymptomatic GIST patients account for 20%.8,9,41,42 Rare manifestations include biliary obstruction, dysphagia, intussusception, and hypoglycemia.

Gastrointestinal bleeding is the most common and the most dangerous complication, often necessitating emergency surgery. The risk of such surgery is significantly higher than that of elective surgery. GIST patients with chronic hemorrhage mainly present with anemia, emaciation, and melena. In cases of acute hemorrhage, the presentation may include peritonitis and shock. Spontaneous rupture of the tumor is rare in GISTs and often occurs in the gastrointestinal tract.43 Most hemorrhagic stromal tumors are associated with intact tunica serosa. Mucosal ulceration or tumor invasion of nutrient vessels leads to bleeding. In Figure 1, the tumor was ulcerated and bleeding was seen under endoscopy. Ulcers cause cancer-like umbilicated lesions. Some controversy remains as to whether these forms represent tumor rupture. Nevertheless, it has been mentioned in the literature that stromal tumors with hemorrhage may be independent risk factors for recurrence of stromal tumors.

The causes of gastrointestinal bleeding in GIST
The causes of intraluminal hemorrhage of GISTs may be related to mucosal and submucosal destruction by tumor growth, invasion of nutrient vessels leading to vascular rupture, tumor necrosis, and the joint action of digestive juices, gastrointestinal peristalsis, and fecal transmission. GISTs are relatively fragile and more vascularized, compared with other common gastrointestinal tumors. In general, by the time symptoms of gastrointestinal bleeding appear, the tumor would already have attained a relatively large size.44 Studies have shown that the proportion of stromal tumor bleeding in the small intestine is much greater than in the stomach.16 This may be related to the size and space of the particular portion of the gastrointestinal tract.

Diagnostic features
In the acute hemorrhagic phase, digital subtraction angiography (DSA) is often positive and has hemostatic effects.45 However, DSA alone cannot distinguish benign from malignant tumors. Definitive diagnosis requires endoscopic ultrasonography (EUS) and pathological examination.46 Some stromal tumors may have "air sign" on plain film as shown in Figure 2, caused by internal bleeding, necrosis, or ulceration. There are few reported cases of bleeding outside the lumen in GISTs. Case reports suggest that trauma or external force may cause rupture and bleeding. The causes of GISTs bleeding are similar to those of other primary gastrointestinal

Figure 1 Endoscopic manifestation of GIST with ulceration and active bleeding. 
Abbreviation: GIST, gastrointestinal stromal tumor.

Figure 2 The enhanced-contrast CT image of a GIST with hemorrhage: the typical "air sign" is caused by hemorrhage and necrosis of the tumor. 
Abbreviation: GIST, gastrointestinal stromal tumor.
malignant tumors; however, the proportion of GISTs that bleed is greater. Therefore, intestinal bleeding should raise the index of suspicion for GISTs. It is believed that the hemorrhage of stromal tumor is related to its pathological, immunohistochemical, or gene mutation type.

Contrast-enhanced CT (ECT) is the most commonly used diagnostic modality for stromal tumors and is used as well for postoperative review and evaluation for recurrence and progression. EUS is also used to diagnose GISTs. By ultrasound, early tumor shows a hypoechoic mass. As the tumor grows, it replaces surrounding structures, forming cystic, necrotic, and bleeding areas. The sensitivity and specificity of EUS for diagnosis of stromal tumors in the stomach and colon are 98% and 64%, respectively. However, the diagnostic efficacy of endoscopic ultrasound-guided Trucut biopsy (EUS-TCB) and EUS-fine needle aspiration (EUS-FNA) are not very good. In addition, these procedures are complicated by pain, bleeding, and fever, among others. The complication rates are 3.3% for EUS-TCB and 8.1% for EUS-FNA. Early stromal tumors rarely metastasize to lymph nodes; however, these tumors tend to be large and they may infiltrate neighboring organs. Unlike other sarcomas, GIST does not metastasize to the bone and lungs. The most common target organs of distant metastasis are liver, peritoneum, and greater omentum.

Traditional surgical methods continue to account for most treatments for stromal tumors, owing to the ease of the operation, and the higher R0 resection rate. Primary GISTs tend to transfer to, rather than invade adjacent structures. Therefore, the conventional wedge resection or local resection can be performed without routine lymph node dissection. The purpose of the surgery is to achieve negative margins (R0 resection). R1 resection or positive margins are not recommended for reoperation. Nevertheless, there is no evidence that the prognosis for R1 resections is worse than R0 resections.

Pathological specimens should be immediately evaluated for capsule rupture. It is recommended to collect fresh or frozen tissues, as new molecular pathology assessments and gene analysis can be performed soon after surgery. For patients with large tumors and chronic bleeding, oral imatinib is recommended. The reduction of tumor volume is expected to achieve optimal surgical outcome and reduce postoperative recurrence. If acute hemorrhage is not controlled, emergency surgical treatment becomes necessary. Approximately 15%–47% of patients have distant metastases at diagnosis, with common sites being the liver, peritoneum,
and omentum. If this is the case, targeted therapy should be performed first. NCCN recommends imatinib prior to surgery as neoadjuvant treatment, including for patients with incomplete resection or high risk of recurrence after resection. It is not recommended that patients with D842V PDGFRA mutations use imatinib because of well-known resistance of these tumors to drugs and TKIs.

The surgery should involve as little disruption of healthy tissue as possible so as to reduce other surgical complications and to improve postoperative quality of life. The target drugs should be discontinued 5–7 days prior to surgery and restarted 2 weeks after surgery. Multidisciplinary team (MDT) methods include endoscopy and pathology. It is necessary for the consultants from departments of radiology, oncology, and surgery to develop individualized treatment regimens.

Small GISTs without gastrointestinal bleeding do not require any particular treatment; however, conventional follow-up remains important. If bleeding occurs, immediate treatment becomes necessary. Many studies indicate that small stromal tumors can be managed expectantly, but when bleeding occurs, there is a high probability of tumor necrosis and ulceration, suggesting that the tumor is developing rapidly, leading to poor prognosis.

Postoperative management of GIST

Genetic testing should be performed routinely to guide the medication regimen. The most recent European consensus proposed that the KIT and PDGFRA gene mutation can be used to analyze and confirm the diagnosis of GISTs, especially in cases with negative CD117. CT is the most effective modality for follow-up. Here, we recommend enhanced abdominal and pelvic CT. In low-risk groups, CT can be performed yearly during the first 5 years. For the middle- and high-risk groups, it is recommended every 6 months. If medication is discontinued, it is recommended that CT examination be performed every 3–4 months during the first 2 years and every 6–12 months in the following 10 years. We suggest that patients with interstitial tumors with hemorrhage be managed similar to the high-risk group.

According to NCCN guidelines, patients in the moderate- and high-risk groups should be treated with imatinib for 1–3 years to reduce the possibility of recurrence. The benefits and tolerability of imatinib for 5 years are currently under study. However, there is not enough scientific evidence to support the imatinib adjuvant therapy in patients with moderate risk. In Table 2, many studies on imatinib and other targeted drugs have gradually changed the postoperative management of GISTs. The usual dose of imatinib is 400 mg/day. The average duration of resistance to imatinib followed by progression is 2–2.5 years. For patients who use imatinib 400 mg/day, if progression occurs, the dose can be increased to 800 mg/day. The higher dose may improve the patients’ progression-free survival and overall survival. KIT exon 9 mutation requires oral administration of 600–800 mg/day, although the dosage has never been prospectively confirmed. The study by Blanke et al suggested that higher doses of imatinib do not improve the survival time due to side effects. However, in GIST patients with exon 9 mutations, the relative risk decreased by 61%. If the higher dose of imatinib is not tolerated, or the disease progresses, sunitinib can provide significant, persistent clinical benefits in patients with imatinib resistance or intolerance. Those who use imatinib preoperatively for neoadjuvant therapy should have a total course of 3 years. But 26% of the patients stopped using imatinib for a variety of reasons. A number of studies have shown that, compared with patients who continued treatment, patients who took imatinib for only 1 year had significantly higher progression rates 3 years later.

Mutations detected during treatment are often resistant to TKIs and are known as secondary mutations. Secondary resistance occurs initially in response to imatinib and progresses to the clonal expansion, making the tumors drug resistant. Secondary resistance occurs initially in response to imatinib and progresses to the clonal expansion, making the tumors drug resistant. If the increased dose of the disease continues to progress, second-line treatment of sunitinib can be considered. George et al showed that sunitinib dose at 37.5 mg/day remained effective, and tolerance was better. Regorafenib, sorfarkinib, ponatinib, and other multi-targeted TKIs can be selected according to the individual conditions. Multidisciplinary approaches with individualized treatment plans are essential.

Prognostic factors

Risk factors for GIST recurrence include location, size, number of mitotic figures, and tumor rupture. Among these, number of mitotic figures is the most important. Whether KIT, PDGFRA mutations, and gastrointestinal bleeding should be added to the risk stratification scheme remains controversial.

In other malignant tumors of the digestive system, hematogenous spread is an important mode of metastasis. Prognosis becomes poor once hematogenous metastasis occurs. Tumor spread occurs easily following rupture and bleeding. Malignant tumor bleeding is often accompanied by infection or perforation, complicating clinical treatment. The opportunity to perform surgery is often lost when the disease is discovered in late stage or when the patient cannot tolerate
surgery. Most tumor bleeding during the perioperative period requires transfusion. One study suggests that perioperative blood transfusion may be related to low immune function, thereby increasing the possibility of tumor recurrence.75 Intraoperative blood loss also impacts prognosis. The less blood loss at surgery, the better the prognosis. This may be due to the fact that bleeding is often related to vascular invasion or serosal involvement.76 Blood from tumors may induce mesothelial cells to release large amounts of cellulose into the peritoneum, giving rise to favorable conditions for tumor implantation and growth.77,78 The 5-year survival rate of gastrointestinal tumors with bleeding and perforation is only 24%, possibly due to peritoneal dissemination.79 However, this mechanism needs further study and confirmation.

Stromal tumor bleeding may be caused by the enhancement of tumor invasion to mucous membrane after gene mutation, leading to hemorrhage caused by destruction of the mucosal layer. Recently, a number of studies have highlighted the ability of GISTs to produce angiogenic factors that not only enhance feeding of tumors but also mediate tumor infiltration. The endothelial cell markers CD31, CD34, and FVIII-Ragd are commonly used to mark neovascularization and tumor growth.80 Although expression of CD117 and CD34 in GIST plays an important role in the diagnosis, the relationship of these markers with bleeding and prognosis is not clear.81

**Conclusion**

In the latest version of the NCCN guidelines, tumor size, location, number of mitotic figures, and tumor rupture are noted as risk factors for grading purposes. Although the mechanism of bleeding in GISTs is not yet fully understood, existing studies suggest that GISTs associated with bleeding tends to indicate poor prognosis. The risk stratification of GIST recurrence is closely related to prognosis, which determines subsequent treatment. We believe that recurrence risk classification of GISTs will improve through future studies. With the increasing popularity of imaging and EUS, the diagnostic success rate of GISTs is increasing. There is a rapid increase in basic research on GISTs. The pathological and biological characteristics are becoming clearer. With the continued appearance of tyrosinase inhibitors, such as

<table>
<thead>
<tr>
<th>Research project</th>
<th>Major researchers</th>
<th>Types and scale of research</th>
<th>Research project</th>
<th>Main research endpoints</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACOSOG Z900029</td>
<td>DeMatteo RP, Ballman KV</td>
<td>Intergroup trial, N=106</td>
<td>Adjuvant imatinib, 400 mg/day 1 year</td>
<td>OS: 1, 3, 5 years</td>
<td>1 year of adjuvant imatinib prolongs OS compared to historical controls</td>
</tr>
<tr>
<td>ACOSOG Z900140</td>
<td>Cortess CL, DeMatteo RP</td>
<td>RCT, N=713</td>
<td>Adjuvant imatinib, 400 mg/day 1 year vs. placebo</td>
<td>RFS, OS</td>
<td>Adjuvant imatinib improves RFS but not OS</td>
</tr>
<tr>
<td>SSGXVIII/AIO82</td>
<td>Major IM</td>
<td>RCT, N=400</td>
<td>Adjuvant imatinib, 400 mg/day 1 year vs. 3 years</td>
<td>RFS</td>
<td>Delayed recurrence due to treatment with longer-term adjuvant imatinib therapy</td>
</tr>
<tr>
<td>Discontinuation of imatinib after 3 years71</td>
<td>Cesne AL</td>
<td>RCT, N=434</td>
<td>Interruption vs. continued imatinib after 3 years</td>
<td>CR, PR, SD</td>
<td>2-year progression-free survival in the continuation group is better than the interruption group</td>
</tr>
<tr>
<td>BFR14 trial83</td>
<td>Patrikoudou A</td>
<td>RCT, N=71</td>
<td>71 non-progressing patients were randomly assigned to the interruption arms after 1, 3, or 5 years. Imatinib was resumed in the case of progressive disease.</td>
<td>CR, PR, SD</td>
<td>Rapid progression after imatinib interruption is associated with poor PFS after reintroduction</td>
</tr>
<tr>
<td>Resumption of imatinib to control metastatic or unresectable GISTs46</td>
<td>Kang YK, Demetri GD</td>
<td>RCT, N=85</td>
<td>Rechallenge with imatinib vs. rechallenge with placebo</td>
<td>PFS</td>
<td>PFS improved in rechallenge group</td>
</tr>
<tr>
<td>EORTC 6202485</td>
<td>Paolo G</td>
<td>RCT, N=908</td>
<td>Adjuvant imatinib, 400 mg/day 2 years vs. observation</td>
<td>IFFS</td>
<td>IFFS not significantly different between the two groups, RFS improved in adjuvant imatinib arm</td>
</tr>
<tr>
<td>PERSIST-5</td>
<td>Raut CP</td>
<td>RCT, N=113</td>
<td>Adjuvant imatinib, 400 mg/day 5 years</td>
<td>RFS</td>
<td>Further reduce the risk of recurrence</td>
</tr>
</tbody>
</table>

**Abbreviations:** CR, complete response; GISTs, gastrointestinal stromal tumors; IFFS, Imatinib failure-free survival; OS, overall survival; PFS, progression-free survival; PR, partial response; RCT, randomized controlled trial; RFS, recurrence-free survival.
imatinib, the prognosis of GISTs has improved significantly. Some late-stage cases that cannot be treated by surgery, as well as patients who cannot use the standard medications, may benefit from MDT and translational medicine. GIST requires multidisciplinary management, which improves both prognosis and quality of life.

Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.

Acknowledgment
This work was supported by Scientific Research of Special-Term Professor from the Educational Department of Liaoning Province, China (Liao Cai Zhi Jiao No. 2012-512).

Disclosure
The authors report no conflicts of interest in this work.

References


Cancer Management and Research

**Publish your work in this journal**

Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.